BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pipe SW, Kruse-Jarres R, Mahlangu JN, Pierce GF, Peyvandi F, Kuebler P, De Ford C, Sanabria F, Ko RH, Chang T, Hay CRM. Establishment of a framework for assessing mortality in persons with congenital hemophilia A and its application to an adverse event reporting database. J Thromb Haemost 2021;19 Suppl 1:21-31. [PMID: 33331042 DOI: 10.1111/jth.15186] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Recht M. Safety first: Tracking adverse events associated with new therapies for people with hemophilia. J Thromb Haemost 2021;19 Suppl 1:3-5. [PMID: 33331044 DOI: 10.1111/jth.15188] [Reference Citation Analysis]
2 Peyvandi F, Mahlangu JN, Pipe SW, Hay CRM, Pierce GF, Kuebler P, Kruse-Jarres R, Shima M. Application of a hemophilia mortality framework to the Emicizumab Global Safety Database. J Thromb Haemost 2021;19 Suppl 1:32-41. [PMID: 33331041 DOI: 10.1111/jth.15187] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
3 Alam AU, Karkhaneh M, Attia T, Wu C, Sun HL. All-cause mortality and causes of death in persons with haemophilia: A systematic review and meta-analysis. Haemophilia 2021;27:897-910. [PMID: 34592037 DOI: 10.1111/hae.14423] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Makris M, Hermans C. Making treatment decisions in hemophilia based on available safety data. J Thromb Haemost 2021;19:1138-9. [PMID: 33792179 DOI: 10.1111/jth.15255] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Pipe SW, Kruse-Jarres R, Mahlangu JN, Pierce GF, Peyvandi F, Kuebler P, De Ford C, Sanabria F, Ko RH, Chang T, Hay CRM. Establishment of a framework for assessing mortality in persons with congenital hemophilia A and its application to an adverse event reporting database. J Thromb Haemost 2021;19 Suppl 1:21-31. [PMID: 33331042 DOI: 10.1111/jth.15186] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
6 Mahlangu J, Iorio A, Kenet G. Emicizumab state-of-the-art update. Haemophilia 2022;28 Suppl 4:103-10. [PMID: 35521723 DOI: 10.1111/hae.14524] [Reference Citation Analysis]